-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target price at $1,225, 29.0x our 2027 EPS view, below LLY's five-year historical forward P/E average. We retain our 2026 EPS at $34.71 and lift our 2027 EPS to $42.22 from $42.12. LLY announced today it is acquiring Kelonia Therapeutics for up to $7B to access its iGPS platform, enabling in vivo CAR-T therapy that reprograms T-cells to fight cancer inside the body via a single IV infusion. Kelonia's lead candidate KLN-1010 targets BCMA in multiple myeloma, the second most frequent U.S. blood cancer. Similarly, LLY announced the acquisition of Orna Therapeutics for up to $1B in February to access its circular RNA platform, which offers longer-lasting protein expression, reduced immunogenicity, and larger genetic payloads versus traditional mRNA. These acquisitions reflect LLY's strategy of deploying GLP-1 cash flow to build a diversified pipeline in oncology, autoimmune diseases and next-generation therapeutic modalities, in our view.